A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor

13612SAGE324-ETD-202Open (affiliates only)A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor324-ETD-202NCT05173012IndustrialAdultTreatmentOtherPagan, FernandoGeorgetown University Medical Center : Luke Lovelace; Lombardi Comprehensive Cancer Center : Luke LovelaceGUMC Neurology10704Luke LovelaceLuke Lovelacell928@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>